On Tuesday, DaVita earned an upgrade to its Relative Strength (RS) Rating, from 68 to 77.
This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks compares to other publicly traded companies.
Decades of market research shows that the best stocks tend to have an RS Rating of above 80 in the early stages of their moves. See if DaVita can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
DaVita is building a consolidation with a 179.60 buy point. See if the stock can break out in heavy trade.
The company showed 20% earnings growth last quarter. Sales gains came in at 5%.
The company earns the No. 7 rank among its peers in the Medical-Outpatient/Home Care industry group. Encompass Health, AdaptHealth and Fresenius Medical Care are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
